{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:54:30Z","timestamp":1793397270565,"version":"4.5.0"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-021-00301-1","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T04:03:21Z","timestamp":1631765001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":164,"title":["Beh\u00e7et syndrome"],"prefix":"10.1038","volume":"7","author":[{"given":"Yusuf","family":"Yazici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hee","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noburu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"301_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici, H., Seyahi, E., Hatemi, G. & Yazici, Y. Beh\u00e7et syndrome: a contemporary view. Nat. Rev. Rheumatol. 14, 107\u2013119 (2018). A comprehensive review of epidemiology, pathogenesis and treatment of Beh\u00e7et syndrome.","journal-title":"Nat. Rev. Rheumatol."},{"key":"301_CR2","doi-asserted-by":"crossref","first-page":"625710","DOI":"10.3389\/fmed.2021.625710","volume":"8","author":"L Ortiz-Fern\u00e1ndez","year":"2021","unstructured":"Ortiz-Fern\u00e1ndez, L. & Sawalha, A. H. Genetics of Beh\u00e7et\u2019s disease: functional genetic analysis and estimating disease heritability. Front. Med. 8, 625710 (2021).","journal-title":"Front. Med."},{"key":"301_CR3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ng.2520","volume":"45","author":"Y Kirino","year":"2013","unstructured":"Kirino, Y. et al. Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et\u2019s disease and epistasis between HLA-B*51 and ERAP1. Nat. Genet. 45, 202\u2013207 (2013). This paper provides information on potential pathways involved in the pathogenesis of Beh\u00e7et syndrome.","journal-title":"Nat. Genet."},{"key":"301_CR4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11739-019-02248-4","volume":"15","author":"J Sota","year":"2020","unstructured":"Sota, J. et al. Beh\u00e7et\u2019s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Intern. Emerg. Med. 15, 1031\u20131039 (2020).","journal-title":"Intern. Emerg. Med."},{"key":"301_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13075-021-02429-7","volume":"23","author":"J Zou","year":"2021","unstructured":"Zou, J. et al. Cluster analysis of phenotypes of patients with Beh\u00e7et\u2019s syndrome: a large cohort study from a referral center in China. Arthritis Res. Ther. 23, 45 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"301_CR6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-020-02406-6","volume":"23","author":"Y Soejima","year":"2021","unstructured":"Soejima, Y. et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Beh\u00e7et\u2019s disease in Japan. Arthritis Res. Ther. 23, 49 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"301_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12016-012-8319-x","volume":"43","author":"H Yazici","year":"2012","unstructured":"Yazici, H., Ugurlu, S. & Seyahi, E. Beh\u00e7et syndrome: is it one condition? Clin. Rev. Allergy Immunol. 43, 275\u2013280 (2012).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"301_CR8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jvsv.2018.11.006","volume":"7","author":"E Seyahi","year":"2019","unstructured":"Seyahi, E. et al. Increased vein wall thickness in Beh\u00e7et disease. J. Vasc. Surg. Venous Lymphat. Disord. 7, 677\u2013684 (2019). This paper describes how blood vessels are involved in Beh\u00e7et syndrome.","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"301_CR9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10067-019-04470-z","volume":"38","author":"F Alibaz-Oner","year":"2019","unstructured":"Alibaz-Oner, F. et al. Venous vessel wall thickness in lower extremity is increased in male patients with Beh\u00e7et\u2019s disease. Clin. Rheumatol. 38, 1447\u20131451 (2019).","journal-title":"Clin. Rheumatol."},{"key":"301_CR10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi, G. et al. Apremilast for Beh\u00e7et\u2019s syndrome \u2014 a phase 2, placebo-controlled study. N. Engl. J. Med. 372, 1510\u20131518 (2015).","journal-title":"N. Engl. J. Med."},{"key":"301_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1034\/j.1399-0039.1999.540301.x","volume":"54","author":"DH Verity","year":"1999","unstructured":"Verity, D. H., Marr, J. E., Ohno, S., Wallace, G. R. & Stanford, M. R. Beh\u00e7et\u2019s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54, 213\u2013220 (1999).","journal-title":"Tissue Antigens"},{"key":"301_CR12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3315\/jdcr.2015.1213","volume":"9","author":"M Ndiaye","year":"2015","unstructured":"Ndiaye, M. et al. Beh\u00e7et\u2019s disease in black skin. A retrospective study of 50 cases in Dakar. J. Dermatol. Case Rep. 9, 98\u2013102 (2015).","journal-title":"J. Dermatol. Case Rep."},{"key":"301_CR13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/kes249","volume":"52","author":"A Mohammad","year":"2012","unstructured":"Mohammad, A., Mandl, T., Sturfelt, G. & Segelmark, M. Incidence, prevalence and clinical characteristics of Beh\u00e7et\u2019s disease in southern Sweden. Rheumatology 52, 304\u2013310 (2012).","journal-title":"Rheumatology"},{"issue":"Suppl. 42","key":"301_CR14","first-page":"S125","volume":"24","author":"NG Papoutsis","year":"2006","unstructured":"Papoutsis, N. G. et al. Prevalence of Adamantiades-Beh\u00e7et\u2019s disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin. Exp. Rheumatol. 24 (Suppl. 42), S125 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR15","first-page":"471","volume":"73","author":"JH Kappen","year":"2015","unstructured":"Kappen, J. H. et al. Beh\u00e7et\u2019s disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth. J. Med. 73, 471\u2013477 (2015).","journal-title":"Neth. J. Med."},{"key":"301_CR16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.24423","volume":"61","author":"KT Calamia","year":"2009","unstructured":"Calamia, K. T. et al. Epidemiology and clinical characteristics of Beh\u00e7et\u2019s disease in the US: a population-based study. Arthritis Rheum. 61, 600\u2013604 (2009).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"301_CR17","first-page":"1284","volume":"62","author":"Y Yazici","year":"2010","unstructured":"Yazici, Y., Filopoulos, M. T., Schimmel, E., McCraken, A. & Swearingen, C. Clinical characteristics, treatment and ethnic\/racial differences in the manifestations of 518 Beh\u00e7et\u2019s syndrome patients in the United States [abstract]. Arthritis Rheum. 62 (Suppl.), 1284 (2010).","journal-title":"Arthritis Rheum."},{"key":"301_CR18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani, C. et al. Epidemiology and clinical course of Beh\u00e7et\u2019s disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum. 57, 171\u2013178 (2007).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 108","key":"301_CR19","first-page":"51","volume":"35","author":"WY Madanat","year":"2017","unstructured":"Madanat, W. Y. et al. The prevalence of Beh\u00e7et\u2019s disease in the north of Jordan: a hospital-based epidemiological survey. Clin. Exp. Rheumatol. 35 (Suppl. 108), 51\u201354 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR20","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane, T., Takeno, M., Suzuki, N. & Inaba, G. Beh\u00e7et\u2019s disease. N. Engl. J. Med. 341, 1284\u20131291 (1999).","journal-title":"N. Engl. J. Med."},{"key":"301_CR21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","volume":"17","author":"A Greco","year":"2018","unstructured":"Greco, A. et al. Beh\u00e7et\u2019s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun. Rev. 17, 567\u2013575 (2018).","journal-title":"Autoimmun. Rev."},{"key":"301_CR22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","volume":"11","author":"M Pineton de Chambrun","year":"2012","unstructured":"Pineton de Chambrun, M., Wechsler, B., Geri, G., Cacoub, P. & Saadoun, D. New insights into the pathogenesis of Beh\u00e7et\u2019s disease. Autoimmun. Rev. 11, 687\u2013698 (2012).","journal-title":"Autoimmun. Rev."},{"key":"301_CR23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(73)93343-6","volume":"2","author":"S Ohno","year":"1973","unstructured":"Ohno, S. et al. HLA-5 and Beh\u00e7et\u2019s disease. Lancet 2, 1383\u20131384 (1973).","journal-title":"Lancet"},{"key":"301_CR24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","volume":"11","author":"D McGonagle","year":"2015","unstructured":"McGonagle, D., Aydin, S. Z., G\u00fcl, A., Mahr, A. & Direskeneli, H. \u2018MHC-Iopathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease. Nat. Rev. Rheumatol. 11, 731\u2013740 (2015). A hypothesis-generating paper on the potential role of MHC in the pathogenesis of Beh\u00e7et syndrome.","journal-title":"Nat. Rev. Rheumatol."},{"key":"301_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.13049","volume":"191","author":"M Giza","year":"2018","unstructured":"Giza, M., Koftori, D., Chen, L. & Bowness, P. Is Beh\u00e7et\u2019s disease a \u2018class1-opathy\u2019? The role of HLA-B*51 in the pathogenesis of Beh\u00e7et\u2019s disease. Clin. Exp. Immunol. 191, 11\u201318 (2018).","journal-title":"Clin. Exp. Immunol."},{"key":"301_CR26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00005792-197409000-00002","volume":"53","author":"JM Moll","year":"1974","unstructured":"Moll, J. M., Haslock, I., Macrae, I. F. & Wright, V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter\u2019s disease, the intestinal arthropathies, and Beh\u00e7et\u2019s syndrome. Medicine 53, 343\u2013364 (1974).","journal-title":"Medicine"},{"key":"301_CR27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki, N. et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et\u2019s disease susceptibility loci. Nat. Genet. 42, 703\u2013706 (2010).","journal-title":"Nat. Genet."},{"key":"301_CR28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers, E. F. et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23RIL12RB2 regions associated with Beh\u00e7et\u2019s disease. Nat. Genet. 42, 698\u2013702 (2010).","journal-title":"Nat. Genet."},{"key":"301_CR29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/14397595.2019.1649103","volume":"30","author":"Y Mizuki","year":"2020","unstructured":"Mizuki, Y. et al. The influence of HLA-B51 on clinical manifestations among Japanese patients with Beh\u00e7et\u2019s disease: a nationwide survey. Mod. Rheumatol. 30, 708\u2013714 (2020).","journal-title":"Mod. Rheumatol."},{"key":"301_CR30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ophtha.2014.09.025","volume":"122","author":"S Hou","year":"2015","unstructured":"Hou, S. et al. Genetic variations of IL17F and IL23A show associations with Beh\u00e7et\u2019s disease and Vogt-Koyanagi-Harada syndrome. Ophthalmology 122, 518\u2013523 (2015).","journal-title":"Ophthalmology"},{"key":"301_CR31","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.38409","volume":"66","author":"T Hughes","year":"2014","unstructured":"Hughes, T. et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Beh\u00e7et\u2019s disease. Arthritis Rheumatol. 66, 1648\u20131658 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"301_CR32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2249.2005.02695.x","volume":"139","author":"Y Imamura","year":"2005","unstructured":"Imamura, Y. et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Beh\u00e7et\u2019s disease. Clin. Exp. Immunol. 139, 371\u2013378 (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"301_CR33","first-page":"249157","volume":"2013","author":"H Direskeneli","year":"2013","unstructured":"Direskeneli, H. Innate and adaptive responses to heat shock proteins in Beh\u00e7et\u2019s disease. Genet. Res. Int. 2013, 249157 (2013).","journal-title":"Genet. Res. Int."},{"key":"301_CR34","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z","volume":"42","author":"MA Frassanito","year":"1999","unstructured":"Frassanito, M. A., Dammacco, R., Cafforio, P. & Dammacco, F. Th1 polarization of the immune response in Beh\u00e7et\u2019s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 42, 1967\u20131974 (1999).","journal-title":"Arthritis Rheum."},{"key":"301_CR35","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1002\/jcb.26809","volume":"119","author":"S Alipour","year":"2018","unstructured":"Alipour, S. et al. Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Beh\u00e7et\u2019s disease. J. Cell. Biochem. 119, 6614\u20136622 (2018).","journal-title":"J. Cell. Biochem."},{"key":"301_CR36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13075-018-1613-0","volume":"20","author":"H Nakano","year":"2018","unstructured":"Nakano, H. et al. GWAS-identified CCR1 and 14 IL10 loci contribute to M1 macrophage-predominant inflammation in Beh\u00e7et\u2019s disease. Arthritis Res. Ther. 20, 124 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"301_CR37","doi-asserted-by":"crossref","first-page":"586558","DOI":"10.3389\/fimmu.2020.586558","volume":"11","author":"SF Perazzio","year":"2020","unstructured":"Perazzio, S. F., Andrade, L. E. C. & de Souza, A. W. S. Understanding Beh\u00e7et\u2019s disease in the context of innate immunity activation. Front. Immunol. 11, 586558 (2020).","journal-title":"Front. Immunol."},{"key":"301_CR38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2249.2011.04543.x","volume":"168","author":"J Shimizu","year":"2012","unstructured":"Shimizu, J. et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-\u0263 in patients with Beh\u00e7et\u2019s disease. Clin. Exp. Immunol. 168, 68\u201374 (2012).","journal-title":"Clin. Exp. Immunol."},{"issue":"3 Suppl. 72","key":"301_CR39","first-page":"35","volume":"30","author":"J Shimizu","year":"2012","unstructured":"Shimizu, J. et al. Skewed TGF\u03b2\/Smad signalling pathway in T cells in patients with Beh\u00e7et\u2019s disease. Clin. Exp. Rheumatol. 30 (3 Suppl. 72), 35\u201339 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR40","first-page":"363859","volume":"2013","author":"J Shimizu","year":"2013","unstructured":"Shimizu, J., Kaneko, F. & Suzuki, N. Skewed helper T-cell responses to IL-12 family cytokines produced by antigen-presenting cells and the genetic background in Beh\u00e7et\u2019s disease. Genet. Res. Int. 2013, 363859 (2013). This paper discusses the important part that T cells play in the pathogenesis of Beh\u00e7et syndrome.","journal-title":"Genet. Res. Int."},{"key":"301_CR41","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s10067-015-2966-2","volume":"35","author":"J Shimizu","year":"2016","unstructured":"Shimizu, J. et al. Possible association of proinflammatory cytokines including IL1\u03b2 and TNF\u03b1 with enhanced Th17 cell differentiation in patients with Beh\u00e7et\u2019s disease. Clin. Rheumatol. 35, 1857\u20131863 (2016).","journal-title":"Clin. Rheumatol."},{"key":"301_CR42","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/jcp.27207","volume":"234","author":"M Ahmadi","year":"2019","unstructured":"Ahmadi, M. et al. Disturbed Th17\/Treg balance, cytokines, and miRNAs in peripheral blood of patients with Beh\u00e7et\u2019s disease. J. Cell. Physiol. 234, 3985\u20133994 (2019).","journal-title":"J. Cell. Physiol."},{"key":"301_CR43","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1002\/jcp.27576","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad, A. et al. Beh\u00e7et\u2019s disease: an immunogenetic perspective. J. Cell. Physiol. 234, 8055\u20138074 (2019).","journal-title":"J. Cell. Physiol."},{"issue":"5 Suppl. 42","key":"301_CR44","first-page":"71","volume":"24","author":"K Hamzaoui","year":"2006","unstructured":"Hamzaoui, K., Hamzaoui, A. & Houman, H. CD4+CD25+ regulatory T cells in patients with Beh\u00e7et\u2019s disease. Clin. Exp. Rheumatol. 24 (5 Suppl. 42), 71\u201378 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR45","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & B\u00e4ckhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332\u20131345 (2016).","journal-title":"Cell"},{"key":"301_CR46","volume":"11","author":"J Shimizu","year":"2016","unstructured":"Shimizu, J. et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Beh\u00e7et\u2019s disease. PLoS ONE 11, e0153746 (2016).","journal-title":"PLoS ONE"},{"key":"301_CR47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10067-018-04419-8","volume":"38","author":"J Shimizu","year":"2019","unstructured":"Shimizu, J. et al. Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Beh\u00e7et\u2019s disease. Clin. Rheumatol. 38, 1437\u20131445 (2019).","journal-title":"Clin. Rheumatol."},{"key":"301_CR48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2014.11.009","volume":"14","author":"C Consolandi","year":"2015","unstructured":"Consolandi, C. et al. Beh\u00e7et\u2019s syndrome patients exhibit specific microbiome signature. Autoimmun. Rev. 14, 269\u2013276 (2015).","journal-title":"Autoimmun. Rev."},{"key":"301_CR49","volume":"6","author":"Y Zi","year":"2018","unstructured":"Zi, Y. et al. A metagenomic study of the gut microbiome in Beh\u00e7et\u2019s disease. Microbiome 6, 135 (2018).","journal-title":"Microbiome"},{"issue":"4 Suppl. 84","key":"301_CR50","first-page":"99","volume":"32","author":"N Ambrose","year":"2014","unstructured":"Ambrose, N., Pierce, I. T., Gatehouse, P. D., Haskard, D. O. & Firmin, D. N. Magnetic resonance imaging of vein wall thickness in patients with Beh\u00e7et\u2019s syndrome. Clin. Exp. Rheumatol. 32 (4 Suppl. 84), 99\u2013102 (2014). This paper reviews the importance and utility of a non-invasive imaging method such as MRI in the management of vascular involvement in Beh\u00e7et syndrome.","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","volume":"27","author":"JK Ahn","year":"2008","unstructured":"Ahn, J. K., Lee, Y. S., Jeon, C. H., Koh, E. M. & Cha, H. S. Treatment of venous thrombosis associated with Beh\u00e7et\u2019s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin. Rheumatol. 27, 201\u2013205 (2008).","journal-title":"Clin. Rheumatol."},{"key":"301_CR52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/00365513.2018.1488179","volume":"78","author":"E Sertoglu","year":"2018","unstructured":"Sertoglu, E. et al. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Beh\u00e7et\u2019s disease. Scand. J. Clin. Lab. Invest. 78, 443\u2013449 (2018).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"301_CR53","volume":"6","author":"E Khan","year":"2016","unstructured":"Khan, E. et al. A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Beh\u00e7et\u2019s syndrome. Sci. Rep. 6, 38104 (2016).","journal-title":"Sci. Rep."},{"key":"301_CR54","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3389\/fimmu.2019.02877","volume":"10","author":"G Emmi","year":"2019","unstructured":"Emmi, G. et al. Stem-cell-derived circulating progenitors dysfunction in Beh\u00e7et\u2019s syndrome patients correlates with oxidative stress. Front. Immunol. 10, 2877 (2019).","journal-title":"Front. Immunol."},{"issue":"Suppl. 121","key":"301_CR55","first-page":"105","volume":"37","author":"NS Yasar Bilge","year":"2019","unstructured":"Yasar Bilge, N. S., Akay, O. M., Gunduz, E., Bilgin, M. & Kasifoglu, T. Circulating endothelial cells in Beh\u00e7et\u2019s disease: is there a relationship with vascular involvement? Clin. Exp. Rheumatol. 37 (Suppl. 121), 105\u2013110 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR56","doi-asserted-by":"crossref","unstructured":"Demirkesen C., Oz B. & G\u00f6ksel S. in Beh\u00e7et Syndrome (eds Yazici, Y., Hatemi, G., Seyahi, E. & Yazici, H.) 171\u2013189 (Springer, 2020).","DOI":"10.1007\/978-3-030-24131-5_12"},{"key":"301_CR57","first-page":"849","volume":"32","author":"K Ureten","year":"2005","unstructured":"Ureten, K. et al. Neutrophil CD64 expression in Beh\u00e7et\u2019s disease. J. Rheumatol. 32, 849\u2013852 (2005).","journal-title":"J. Rheumatol."},{"key":"301_CR58","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/ar2608","volume":"11","author":"JD Canete","year":"2009","unstructured":"Canete, J. D. et al. Distinct synovial immunopathology in Beh\u00e7et disease and psoriatic arthritis. Arthritis Res. Ther. 11, R17 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"301_CR59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2559.2004.01954.x","volume":"45","author":"N Hayasaki","year":"2004","unstructured":"Hayasaki, N. et al. Neutrophilic phlebitis is characteristic of intestinal Beh\u00e7et\u2019s disease and simple ulcer syndrome. Histopathology 45, 377\u2013383 (2004).","journal-title":"Histopathology"},{"key":"301_CR60","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.4049\/jimmunol.177.9.6415","volume":"177","author":"M Melikoglu","year":"2006","unstructured":"Melikoglu, M. et al. Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J. Immunol. 177, 6415\u20136421 (2006).","journal-title":"J. Immunol."},{"key":"301_CR61","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1046\/j.1365-4362.1998.00474.x","volume":"37","author":"T Ergun","year":"1998","unstructured":"Ergun, T., G\u00fcrb\u00fcz, O., Harvell, J., Jorizzo, J. & White, W. The histopathology of pathergy: a chronologic study of skin hyperreactivity in Beh\u00e7et\u2019s disease. Int. J. Dermatol. 37, 929\u2013933 (1998).","journal-title":"Int. J. Dermatol."},{"key":"301_CR62","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2559.2000.00859.x","volume":"36","author":"M Kobayashi","year":"2000","unstructured":"Kobayashi, M. et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Beh\u00e7et disease. Histopathology 36, 362\u2013371 (2000).","journal-title":"Histopathology"},{"key":"301_CR63","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","volume":"10","author":"G Emmi","year":"2019","unstructured":"Emmi, G. et al. Beh\u00e7et\u2019s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front. Immunol. 10, 1085 (2019).","journal-title":"Front. Immunol."},{"key":"301_CR64","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","volume":"78","author":"A Le Joncour","year":"2019","unstructured":"Le Joncour, A. et al. Critical role of neutrophil extracellular traps (NETs) in patients with Beh\u00e7et\u2019s disease. Ann. Rheum. Dis. 78, 1274\u20131282 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"301_CR65","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease.","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease. Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335, 1078\u20131080 (1990).","journal-title":"Lancet"},{"key":"301_CR66","first-page":"338","volume":"28","author":"F Davatchi","year":"2013","unstructured":"Davatchi, F. et al. The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol. 28, 338\u2013347 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"301_CR67","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-017-1463-y","volume":"18","author":"T Blake","year":"2017","unstructured":"Blake, T. et al. Birmingham Beh\u00e7et\u2019s service: classification of disease and application of the 2014 International Criteria for Beh\u00e7et\u2019s Disease (ICBD) to a UK cohort. BMC Musculoskelet. Disord. 18, 101 (2017).","journal-title":"BMC Musculoskelet. Disord."},{"key":"301_CR68","first-page":"291","volume":"18","author":"Beh\u00e7et\u2019s Disease Research Committee of Japan.","year":"1974","unstructured":"Beh\u00e7et\u2019s Disease Research Committee of Japan. Beh\u00e7et\u2019s disease guide to diagnosis of Beh\u00e7et\u2019s disease. Jpn. J. Ophthalmol. 18, 291\u2013294 (1974).","journal-title":"Jpn. J. Ophthalmol."},{"key":"301_CR69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","volume":"4","author":"M Suzuki Kurokawa","year":"2004","unstructured":"Suzuki Kurokawa, M. & Suzuki, N. Behcet\u2019s disease. Clin. Exp. Med. 4, 10\u201320 (2004).","journal-title":"Clin. Exp. Med."},{"issue":"Suppl. 2","key":"301_CR70","first-page":"619","volume":"76","author":"Z Kutlubay","year":"2017","unstructured":"Kutlubay, Z. et al. Papulopustular lesions according to age, sex and localization in Beh\u00e7et\u2019s syndrome patients compared with healthy and diseased controls [abstract FRI0351]. Ann. Rheum. Dis. 76 (Suppl. 2), 619 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"301_CR71","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/31.11.767","volume":"31","author":"DM Main","year":"1992","unstructured":"Main, D. M. & Chamberlain, M. A. Clinical differentiation of oral ulceration in Beh\u00e7et\u2019s disease. Br. J. Rheumatol. 31, 767\u2013770 (1992).","journal-title":"Br. J. Rheumatol."},{"key":"301_CR72","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1111\/j.1365-2230.2009.03384.x","volume":"34","author":"SH Oh","year":"2009","unstructured":"Oh, S. H., Han, E. C., Lee, J. H. & Bang, D. Comparison of the clinical features of recurrent aphthous stomatitis and Beh\u00e7et\u2019s disease. Clin. Exp. Dermatol. 34, e208\u2013e212 (2009).","journal-title":"Clin. Exp. Dermatol."},{"key":"301_CR73","unstructured":"Hatemi G. et al. Pentoxifylline gel for oral ulcers in patients with Beh\u00e7et\u2019s syndrome [abstract 1720]. Presented at the 2019 ACR\/ARP Annual Meeting. https:\/\/acrabstracts.org\/abstract\/pentoxifylline-gel-for-oral-ulcers-in-patients-with-behcets-syndrome\/ (2019)."},{"key":"301_CR74","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-4632.2006.02859.x","volume":"45","author":"MC Mat","year":"2006","unstructured":"Mat, M. C., Goksugur, N., Engin, B., Yurdakul, S. & Yazici, H. The frequency of scarring after genital ulcers in Beh\u00e7et\u2019s syndrome: a prospective study. Int. J. Dermatol. 45, 554\u2013556 (2006).","journal-title":"Int. J. Dermatol."},{"key":"301_CR75","first-page":"482","volume":"55","author":"MA Kanakis","year":"2017","unstructured":"Kanakis, M. A., Vaiopoulos, A. G., Vaiopoulos, G. A. & Kaklamanis, P. G. Epididymo-orchitis in Beh\u00e7et\u2019s disease: a review of the wide spectrum of the disease. Acta Med. Iran. 55, 482\u2013485 (2017).","journal-title":"Acta Med. Iran."},{"key":"301_CR76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1309\/GCTH-0060-55K8-XCTT","volume":"116","author":"C Demirkesen","year":"2001","unstructured":"Demirkesen, C. et al. Clinicopathologic evaluation of nodular cutaneous lesions of Beh\u00e7et syndrome. Am. J. Clin. Pathol. 116, 341\u2013346 (2001).","journal-title":"Am. J. Clin. Pathol."},{"key":"301_CR77","first-page":"2393","volume":"29","author":"R Tunc","year":"2002","unstructured":"Tunc, R., Keyman, E., Melikoglu, M., Fresko, I. & Yazici, H. Target organ associations in Turkish patients with Beh\u00e7et\u2019s disease: a cross sectional study by exploratory factor analysis. J. Rheumatol. 29, 2393\u20132396 (2002).","journal-title":"J. Rheumatol."},{"key":"301_CR78","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","volume":"48","author":"P Leccese","year":"2019","unstructured":"Leccese, P. et al. Management of skin, mucosa and joint involvement of Beh\u00e7et\u2019s syndrome: A systematic review for update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Semin. Arthritis Rheum. 48, 752\u2013762 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"301_CR79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/1756-185X.12633","volume":"20","author":"A Fatemi","year":"2017","unstructured":"Fatemi, A. et al. Prospective study of articular manifestations in Beh\u00e7et\u2019s disease: five-year report. Int. J. Rheum. Dis. 20, 97\u2013102 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"301_CR80","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/ard.60.11.1074","volume":"60","author":"E Diri","year":"2001","unstructured":"Diri, E. et al. Papulopustular skin lesions are seen more frequently in patients with Beh\u00e7et\u2019s syndrome who have arthritis: a controlled and masked study. Ann. Rheum. Dis. 60, 1074\u20131076 (2001).","journal-title":"Ann. Rheum. Dis."},{"key":"301_CR81","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/ard.2003.017467","volume":"63","author":"G Hatemi","year":"2004","unstructured":"Hatemi, G. et al. The pustular skin lesions in Beh\u00e7et\u2019s syndrome are not sterile. Ann. Rheum. Dis. 63, 1450\u20131452 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"301_CR82","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/art.23450","volume":"58","author":"G Hatemi","year":"2008","unstructured":"Hatemi, G., Fresko, I., Tascilar, K. & Yazici, H. Increased enthesopathy among Beh\u00e7et\u2019s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum. 58, 1539\u20131545 (2008).","journal-title":"Arthritis Rheum."},{"key":"301_CR83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.27181","volume":"62","author":"G Hatemi","year":"2010","unstructured":"Hatemi, G. et al. Reply to letter by Priori et al commenting on whether Beh\u00e7et\u2019s syndrome patients with acne and arthritis comprise a true subset. Arthritis Rheum. 62, 305\u2013306 (2010).","journal-title":"Arthritis Rheum."},{"issue":"6 Suppl. 94","key":"301_CR84","first-page":"107","volume":"33","author":"D Buyuktas","year":"2105","unstructured":"Buyuktas, D. et al. Fatigue is correlated with disease activity but not with the type of organ involvement in Beh\u00e7et\u2019s syndrome: a comparative clinical survey. Clin. Exp. Rheumatol. 33 (6 Suppl. 94), 107\u2013112 (2105).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl. 1","key":"301_CR85","volume":"16","author":"I Kone-Paut","year":"2021","unstructured":"Kone-Paut, I. et al. French recommendations for the management of Beh\u00e7et\u2019s disease. Orphanet. J. Rare Dis. 16 (Suppl. 1), 352 (2021).","journal-title":"Orphanet. J. Rare Dis."},{"key":"301_CR86","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun, I., Onal, S., Altan-Yaycioglu, R., Huseyin Altunbas, H. & Urgancioglu, M. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am. J. Ophthalmol. 138, 373\u2013380 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"301_CR87","doi-asserted-by":"publisher","unstructured":"Tugal-Tutkun, I. et al. An algorithm for the diagnosis of Beh\u00e7et disease uveitis in adults. Ocul. Immunol. Inflamm. https:\/\/doi.org\/10.1080\/09273948.2020.1736310 (2020).","DOI":"10.1080\/09273948.2020.1736310"},{"key":"301_CR88","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/IAE.0000000000001587","volume":"38","author":"S Onal","year":"2018","unstructured":"Onal, S. et al. Quantitative analysis of structural alterations in the choroid of patients with active Beh\u00e7et uveitis. Retina 38, 828\u2013840 (2018).","journal-title":"Retina"},{"key":"301_CR89","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1097\/IAE.0000000000001418","volume":"37","author":"M Khairallah","year":"2017","unstructured":"Khairallah, M. et al. Optical coherence tomography angiography in patients with Beh\u00e7et uveitis. Retina 37, 1678\u20131691 (2017).","journal-title":"Retina"},{"key":"301_CR90","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09273948.2013.795228","volume":"21","author":"I Tugal-Tutkun","year":"2013","unstructured":"Tugal-Tutkun, I., Gupta, V. & Cunningham, E. T. Differential diagnosis of Beh\u00e7et uveitis. Ocul. Immunol. Inflamm. 21, 337\u2013350 (2013).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"301_CR91","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","volume":"53","author":"K Tascilar","year":"2014","unstructured":"Tascilar, K. et al. Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course. Rheumatology 53, 2018\u20132022 (2014).","journal-title":"Rheumatology"},{"key":"301_CR92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","volume":"91","author":"E Seyahi","year":"2012","unstructured":"Seyahi, E. et al. Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients. Medicine 91, 35\u201348 (2012).","journal-title":"Medicine"},{"key":"301_CR93","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","volume":"59","author":"Y Ozguler","year":"2020","unstructured":"Ozguler, Y. et al. Clinical course of acute deep vein thrombosis of the legs in Beh\u00e7et\u2019s syndrome. Rheumatology 59, 799\u2013806 (2020).","journal-title":"Rheumatology"},{"key":"301_CR94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/BOR.0000000000000562","volume":"31","author":"U Uyguno\u011flu","year":"2019","unstructured":"Uyguno\u011flu, U. & Siva, A. Nervous system involvement in Beh\u00e7et\u2019s syndrome. Curr. Opin. Rheumatol. 31, 32\u201339 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"301_CR95","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-018-0843-5","volume":"18","author":"U Uyguno\u011flu","year":"2018","unstructured":"Uyguno\u011flu, U. & Siva, A. Beh\u00e7et\u2019s syndrome and nervous system involvement. Curr. Neurol. Neurosci. Rep. 18, 35 (2018).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"301_CR96","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/1756-185X.13542","volume":"22","author":"D Alis","year":"2019","unstructured":"Alis, D. et al. Apparent diffusion coefficient characteristics of parenchymal neuro-Beh\u00e7et\u2019s disease. Int. J. Rheum. Dis. 22, 1452\u20131458 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"301_CR97","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir, G., Serdaroglu, P. & Tas\u00e7i, B. Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group. Brain 122, 2171\u20132182 (1999).","journal-title":"Brain"},{"key":"301_CR98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02604297","volume":"24","author":"Y Kasahara","year":"1981","unstructured":"Kasahara, Y. et al. Intestinal involvement in Beh\u00e7et\u2019s disease: review of 136 surgical cases in the Japanese literature. Dis. Colon. Rectum 24, 103\u2013106 (1981).","journal-title":"Dis. Colon. Rectum"},{"key":"301_CR99","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s10620-012-2351-9","volume":"58","author":"YS Jung","year":"2013","unstructured":"Jung, Y. S. et al. Clinical course of intestinal Beh\u00e7et\u2019s disease during the first five years. Dig. Dis. Sci. 58, 496\u2013503 (2013).","journal-title":"Dig. Dis. Sci."},{"key":"301_CR100","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/ibd.21517","volume":"17","author":"YS Jung","year":"2011","unstructured":"Jung, Y. S. et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Beh\u00e7et\u2019s disease. Inflamm. Bowel Dis. 17, 1594\u20131602 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"301_CR101","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00054725-200108000-00010","volume":"7","author":"CR Lee","year":"2001","unstructured":"Lee, C. R. et al. Colonoscopic findings in intestinal Beh\u00e7et\u2019s disease. Inflamm. Bowel Dis. 7, 243\u2013249 (2001).","journal-title":"Inflamm. Bowel Dis."},{"key":"301_CR102","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/BOR.0000000000000125","volume":"27","author":"JH Cheon","year":"2015","unstructured":"Cheon, J. H. & Kim, W. H. An update on the diagnosis, treatment, and prognosis of intestinal Beh\u00e7et\u2019s disease. Curr. Opin. Rheumatol. 27, 24\u201331 (2015).","journal-title":"Curr. Opin. Rheumatol."},{"key":"301_CR103","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00004836-200003000-00006","volume":"30","author":"Y Bayraktar","year":"2000","unstructured":"Bayraktar, Y., Ozaslan, E. & Van Thiel, D. H. Gastrointestinal manifestations of Beh\u00e7et\u2019s disease. J. Clin. Gastroenterol. 30, 144\u2013154 (2000).","journal-title":"J. Clin. Gastroenterol."},{"key":"301_CR104","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi, E. et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82, 60\u201376 (2003). The largest and longest followed cohort of patients with Beh\u00e7et syndrome including findings related to the natural history of this condition.","journal-title":"Medicine"},{"key":"301_CR105","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi, G. et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann. Rheum. Dis. 77, 808\u2013818 (2018). The latest treatment guidelines for Beh\u00e7et syndrome.","journal-title":"Ann. Rheum. Dis."},{"key":"301_CR106","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi, G. et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N. Engl. J. Med. 381, 1918\u20131928 (2019). This paper presents data on the first approved treatment for oral ulcers in Beh\u00e7et syndrome in the USA.","journal-title":"N. Engl. J. Med."},{"key":"301_CR107","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","volume":"71","author":"A Mirouse","year":"2019","unstructured":"Mirouse, A. et al. Long-term outcome of ustekinumab therapy for Beh\u00e7et\u2019s disease. Arthritis Rheumatol. 71, 1727\u20131732 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"301_CR108","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","volume":"79","author":"F Fagni","year":"2020","unstructured":"Fagni, F. et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: a multicentre study. Ann. Rheum. Dis. 79, 1098\u20131104 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"301_CR109","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","volume":"27","author":"G Lopalco","year":"2017","unstructured":"Lopalco, G. et al. Certolizumab Pegol treatment in Beh\u00e7et\u2019s disease with different organ involvement: a multicenter retrospective observational study. Mod. Rheumatol. 27, 1031\u20131035 (2017).","journal-title":"Mod. Rheumatol."},{"key":"301_CR110","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale, A. et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease. Clin. Rheumatol. 36, 2063\u20132069 (2017).","journal-title":"Clin. Rheumatol."},{"key":"301_CR111","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bjoms.2020.07.027","volume":"58","author":"A Senusi","year":"2020","unstructured":"Senusi, A. et al. New mouthwash: an efficacious intervention for oral ulceration associated with Beh\u00e7et\u2019s disease. Br. J. Oral. Maxillofac. Surg. 58, 1034\u20131039 (2020).","journal-title":"Br. J. Oral. Maxillofac. Surg."},{"key":"301_CR112","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler, Y. et al. Management of major organ involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology 57, 2200\u20132212 (2018).","journal-title":"Rheumatology"},{"key":"301_CR113","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","volume":"70","author":"G Emmi","year":"2018","unstructured":"Emmi, G. et al. Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s syndrome: a retrospective study of seventy patients with vascular involvement. Arthritis Rheumatol. 70, 1500\u20131507 (2018).","journal-title":"Arthritis Rheumatol."},{"issue":"4 Suppl. 34","key":"301_CR114","first-page":"1","volume":"22","author":"V Hamuryudan","year":"2004","unstructured":"Hamuryudan, V., Oz, B., T\u00fcz\u00fcn, H. & Yazici, H. The menacing pulmonary artery aneurysms of Beh\u00e7et\u2019s syndrome. Clin. Exp. Rheumatol. 22 (4 Suppl. 34), 1\u20133 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/keq330","volume":"50","author":"X Liu","year":"2011","unstructured":"Liu, X., Yang, P., Wang, C., Li, F. & Kijlstra, A. IFN-\u03b1 blocks IL-17 production by peripheral blood mononuclear cells in Beh\u00e7et\u2019s disease. Rheumatology 50, 293\u2013298 (2011).","journal-title":"Rheumatology"},{"key":"301_CR116","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","volume":"45","author":"V Hamuryudan","year":"2015","unstructured":"Hamuryudan, V. et al. Pulmonary artery involvement in Beh\u00e7et\u2019s syndrome: effects of anti-TNF treatment. Semin. Arthritis Rheum. 45, 369\u2013373 (2015).","journal-title":"Semin. Arthritis Rheum."},{"key":"301_CR117","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","volume":"197","author":"AC Desbois","year":"2018","unstructured":"Desbois, A. C. et al. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Beh\u00e7et\u2019s disease: a multicenter observational study of 18 patients. Clin. Immunol. 197, 54\u201359 (2018).","journal-title":"Clin. Immunol."},{"key":"301_CR118","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/1756-185X.13778","volume":"23","author":"A Aksoy","year":"2020","unstructured":"Aksoy, A. et al. Efficacy of TNF\u03b1 inhibitors for refractory vascular Beh\u00e7et\u2019s disease: a multicenter observational study of 27 patients and a review of the literature. Int. J. Rheum. Dis. 23, 256\u2013261 (2020).","journal-title":"Int. J. Rheum. Dis."},{"key":"301_CR119","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.38351","volume":"66","author":"N Noel","year":"2014","unstructured":"Noel, N. et al. Long-term outcome of neuro-Beh\u00e7et\u2019s disease. Arthritis Rheumatol. 66, 1306\u20131314 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"301_CR120","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000258","volume":"3","author":"B Zeydan","year":"2016","unstructured":"Zeydan, B. et al. Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease. Neurol. Neuroimmunol. Neuroinflamm. 3, e258 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"301_CR121","unstructured":"Atienza-Mateo B. et al. Tocilizumab in Beh\u00e7et\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes. Clin. Exp. Rheumatol. (in the press)."},{"key":"301_CR122","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09273948.2013.866257","volume":"22","author":"M Zierhut","year":"2014","unstructured":"Zierhut, M., Abu El-Asrar, A. M., Bodaghi, B. & Tugal-Tutkun, I. Therapy of ocular Beh\u00e7et disease. Ocul. Immunol. Inflamm. 22, 64\u201376 (2014).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"301_CR123","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e3283368099","volume":"22","author":"I Kotter","year":"2010","unstructured":"Kotter, I., Hamuryudan, V., Ozturk, Z. E. & Yazici, H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr. Opin. Rheumatol. 22, 278\u2013283 (2010).","journal-title":"Curr. Opin. Rheumatol."},{"key":"301_CR124","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis, P. P. et al. Anti-TNF therapy in the management of Beh\u00e7et\u2019s disease\u2013review and basis for recommendations. Rheumatology 46, 736\u2013741 (2007).","journal-title":"Rheumatology"},{"key":"301_CR125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/09273948.2015.1042167","volume":"23","author":"E Coskun","year":"2015","unstructured":"Coskun, E. et al. Intravitreal dexamethasone implant for treatment of refractory Beh\u00e7et posterior uveitis: one-year follow-up results. Ocul. Immunol. Inflamm. 23, 437\u2013443 (2015).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"301_CR126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09273948.2016.1215472","volume":"26","author":"AK Reddy","year":"2018","unstructured":"Reddy, A. K., Burkholder, B. M., Khan, I. R. & Thorne, J. E. Iluvien implantation for uveitis and uveitic macular edema. Ocul. Immunol. Inflamm. 26, 315\u2013316 (2018).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"301_CR127","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu, T. et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Beh\u00e7et\u2019s disease: indication of anti-TNF\u03b1 monoclonal antibodies. J. Gastroenterol. 49, 156\u2013162 (2014).","journal-title":"J. Gastroenterol."},{"key":"301_CR128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe, K. et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Beh\u00e7et\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J. Gastroenterol. 55, 679\u2013700 (2020).","journal-title":"J. Gastroenterol."},{"key":"301_CR129","first-page":"S140","volume":"32","author":"AG Vaiopoulos","year":"2014","unstructured":"Vaiopoulos, A. G., Sfikakis, P. P., Kanakis, M. A., Vaiopoulos, G. & Kaklamanis, P. G. Gastrointestinal manifestations of Beh\u00e7et\u2019s disease: advances in evaluation and management. Clin. Exp. Rheumatol. 32, S140\u2013S148 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR130","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida, S. et al. Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin. Gastroenterol. Hepatol. 13, 940\u2013948 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"301_CR131","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5217\/ir.2020.00013","volume":"19","author":"Y Suzuki","year":"2021","unstructured":"Suzuki, Y. et al. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Beh\u00e7et\u2019s disease: results from a large real-world observational study. Intest. Res. 19, 301\u2013312 (2021).","journal-title":"Intest. Res."},{"key":"301_CR132","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5217\/ir.2017.15.3.311","volume":"15","author":"HJ Lee","year":"2017","unstructured":"Lee, H. J. & Cheon, J. H. Optimal diagnosis and disease activity monitoring of intestinal Beh\u00e7et\u2019s disease. Intest. Res. 15, 311\u2013317 (2017). A summary of the diagnostic approach to intestinal involvement in Beh\u00e7et syndrome.","journal-title":"Intest. Res."},{"issue":"Suppl. 108","key":"301_CR133","first-page":"43","volume":"35","author":"AA Senusi","year":"2017","unstructured":"Senusi, A. A., Ola, D., Mather, J., Mather, J. & Fortune, F. Beh\u00e7et\u2019s syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status. Clin. Exp. Rheumatol. 35 (Suppl. 108), 43\u201350 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR134","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11739-017-1691-z","volume":"12","author":"C Fabiani","year":"2017","unstructured":"Fabiani, C. et al. Quality of life impairment in Beh\u00e7et\u2019s disease and relationship with disease activity: a prospective study. Intern. Emerg. Med. 12, 947\u2013955 (2017).","journal-title":"Intern. Emerg. Med."},{"key":"301_CR135","first-page":"1","volume":"17","author":"A Khabbazi","year":"2021","unstructured":"Khabbazi, A., Ebrahimzadeh Attari, V., Asghari Jafarabadi, M. & Malek Mahdavi, A. Quality of life in patients with Beh\u00e7et disease and its relation with clinical symptoms and disease activity. Rheumatol. Clin. 17, 1\u20136 (2021).","journal-title":"Rheumatol. Clin."},{"key":"301_CR136","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1756-185X.13411","volume":"22","author":"S Can Sandikci","year":"2019","unstructured":"Can Sandikci, S., Colak, S., Omma, A. & Enecik, M. E. An evaluation of depression, anxiety and fatigue in patients with Beh\u00e7et\u2019s disease. Int. J. Rheum. Dis. 22, 974\u2013979 (2019).","journal-title":"Int. J. Rheum. Dis."},{"issue":"6 Suppl. 94","key":"301_CR137","first-page":"30","volume":"33","author":"C Saygin","year":"2015","unstructured":"Saygin, C., Uzunaslan, D., Hatemi, G. & Hamuryudan, V. Suicidal ideation among patients with Beh\u00e7et\u2019s syndrome. Clin. Exp. Rheumatol. 33 (6 Suppl. 94), 30\u201335 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR138","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0341-7","volume":"10","author":"A Senusi","year":"2015","unstructured":"Senusi, A., Seoudi, N., Bergmeier, L. A. & Fortune, F. Genital ulcer severity score and genital health quality of life in Beh\u00e7et\u2019s disease. Orphanet. J. Rare Dis. 10, 117 (2015).","journal-title":"Orphanet. J. Rare Dis."},{"key":"301_CR139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00296-019-04455-w","volume":"40","author":"R Talarico","year":"2020","unstructured":"Talarico, R. et al. Sexual dysfunction in Beh\u00e7et\u2019s syndrome. Rheumatol. Int. 40, 9\u201315 (2020).","journal-title":"Rheumatol. Int."},{"key":"301_CR140","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1756-185x.12005","volume":"16","author":"DO Yetkin","year":"2013","unstructured":"Yetkin, D. O., Celik, O., Hatemi, G. & Kadioglu, P. Sexual dysfunction and depression in premenopausal women with mucocutaneous Beh\u00e7et\u2019s disease. Int. J. Rheum. Dis. 16, 463\u2013468 (2013).","journal-title":"Int. J. Rheum. Dis."},{"key":"301_CR141","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/rheumatology\/kel382","volume":"46","author":"N Sut","year":"2007","unstructured":"Sut, N., Seyahi, E., Yurdakul, S., Senocak, M. & Yazici, H. A cost analysis of Beh\u00e7et\u2019s syndrome in Turkey. Rheumatology 46, 678\u2013682 (2007).","journal-title":"Rheumatology"},{"key":"301_CR142","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3906\/sag-1603-161","volume":"47","author":"G Mumcu","year":"2017","unstructured":"Mumcu, G. et al. The assessment of work productivity and activity impairment in Beh\u00e7et\u2019s disease. Turk. J. Med. Sci. 47, 535\u2013541 (2017).","journal-title":"Turk. J. Med. Sci."},{"issue":"4 Suppl. 84","key":"301_CR143","first-page":"173","volume":"32","author":"P Mehta","year":"2014","unstructured":"Mehta, P., Ambrose, N. & Haskard, D. O. Work-related disability in Beh\u00e7et\u2019s syndrome: a British case series. Clin. Exp. Rheumatol. 32 (4 Suppl. 84), 173\u2013174 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24511","author":"G Hatemi","year":"2020","unstructured":"Hatemi, G. et al. The OMERACT core set of domains for outcome measures in Beh\u00e7et syndrome. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.24511 (2020).","journal-title":"Arthritis Care Res."},{"key":"301_CR145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.131249","volume":"41","author":"G Hatemi","year":"2014","unstructured":"Hatemi, G. et al. Outcome measures used in clinical trials for Beh\u00e7et syndrome: a systematic review. J. Rheumatol. 41, 599\u2013612 (2014).","journal-title":"J. Rheumatol."},{"key":"301_CR146","first-page":"931","volume":"31","author":"G Gilworth","year":"2004","unstructured":"Gilworth, G. et al. Development of the BD-QoL: a quality of life measure specific to Beh\u00e7et\u2019s disease. J. Rheumatol. 31, 931\u2013937 (2004).","journal-title":"J. Rheumatol."},{"issue":"Suppl. 121","key":"301_CR147","first-page":"28","volume":"37","author":"Y Ozguler","year":"2019","unstructured":"Ozguler, Y. et al. Patients\u2019 experiences with Beh\u00e7et\u2019s syndrome: structured interviews among patients with different types of organ involvement. Clin. Exp. Rheumatol. 37 (Suppl. 121), 28\u201334 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR148","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","volume":"43","author":"G Lawton","year":"2004","unstructured":"Lawton, G., Bhakta, B. B., Chamberlain, M. A. & Tennant, A. The Beh\u00e7et\u2019s disease activity index. Rheumatology 43, 73\u201378 (2004).","journal-title":"Rheumatology"},{"key":"301_CR149","first-page":"360","volume":"67","author":"C Forbess","year":"2008","unstructured":"Forbess, C., Swearingen, C. & Yazici, Y. Beh\u00e7et\u2019s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Beh\u00e7et\u2019s Disease Current Activity Form (BDCAF). Ann. Rheum. Dis. 67, 360 (2008).","journal-title":"Ann. Rheum. Dis."},{"issue":"4 Suppl. 84","key":"301_CR150","first-page":"80","volume":"32","author":"G Mumcu","year":"2014","unstructured":"Mumcu, G., Inanc, N., Taze, A., Ergun, T. & Direskeneli, H. A new mucocutaneous activity index for Beh\u00e7et\u2019s disease. Clin. Exp. Rheumatol. 32 (4 Suppl. 84), 80\u201386 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"301_CR151","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00296-018-4117-y","volume":"38","author":"A Senusi","year":"2018","unstructured":"Senusi, A., Higgins, S. & Fortune, F. The influence of oral health and psycho-social well-being on clinical outcomes in Beh\u00e7et\u2019s disease. Rheumatol. Int. 38, 1873\u20131883 (2018).","journal-title":"Rheumatol. Int."},{"key":"301_CR152","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon, J. H. et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et\u2019s disease. Inflamm. Bowel. Dis. 17, 605\u2013613 (2011).","journal-title":"Inflamm. Bowel. Dis."},{"key":"301_CR153","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/ker423","volume":"51","author":"M Karaca","year":"2012","unstructured":"Karaca, M., Hatemi, G., Sut, N. & Yazici, H. The papulopustular lesion\/arthritis cluster of Beh\u00e7et\u2019s syndrome also clusters in families. Rheumatology 51, 1053\u20131060 (2012).","journal-title":"Rheumatology"},{"key":"301_CR154","volume":"7","author":"SW Kim","year":"2017","unstructured":"Kim, S. W. et al. Identification of genetic susceptibility loci for intestinal Beh\u00e7et\u2019s disease. Sci. Rep. 7, 39850 (2017).","journal-title":"Sci. Rep."},{"key":"301_CR155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-016-1115-x","volume":"18","author":"Y Kirino","year":"2016","unstructured":"Kirino, Y. et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Beh\u00e7et\u2019s disease: a retrospective observational study. Arthritis Res. Ther. 18, 217 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"301_CR156","doi-asserted-by":"crossref","unstructured":"Yazici, Y., Hatemi, G., Seyahi, E. & Yazici, H. (eds) Beh\u00e7et Syndrome (Springer, 2019).","DOI":"10.1007\/978-3-030-24131-5"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00301-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00301-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00301-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T19:50:28Z","timestamp":1670010628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00301-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1038\/s41572-021-00301-1","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"11 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.Y. has received consulting fees from Amgen and research support from Amgen, BMS and Genentech. G.H. has received research grant, lecture fees and fees for serving on an advisory board from Celgene; consulting fees from Bayer, Johnson & Johnson and UCB Pharma; and lecture fees from Abbvie, Amgen, Novartis and UCB Pharma. B.B. has received consulting fees from AbbVie\/Allergan, Alimera, Horus Pharma, Novartis, Santen and Thea. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}